# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K052499   
B. Purpose for Submission: New device(s)   
C. Measurand: Influenza A and B nucleoprotein antigens   
D. Type of Test: Rapid chromatographic immunoassay that differentiates influenza A from influenza B virus   
E. Applicant: Genzyme Corporation   
F. Proprietary and Established Names: ® Influenza OSOM A&B Test G. Regulatory Information: 1. Regulation section: 21CFR 866.3330; Influenza Virus Serological Reagents 2. Classification: Class: I 3. Product code: GNX, Antigens, CF, including CF controls, Influenza A, B, and C. 4. Panel: 83 Microbiology   
H. Intended Use:

The OSOM Influenza A&B Test is an in vitro diagnostic immunochromatographic assay intended for the qualitative detection of influenza A and influenza B viral antigens from nasal swab specimens. It is intended to aid in the rapid differential diagnosis of influenza A and/or B viral infections. A negative test is presumptive and should be confirmed by cell culture.

Cross-reactivity with other respiratory viruses in this assay has not been

# evaluated. The user is responsible for determining the cross-reactivity of other respiratory viruses with this test.

# 2. Indication(s) for use:

The OSOM Influenza A&B Test is an in vitro diagnostic immunochromatographic assay intended for the qualitative detection of influenza A and influenza B viral antigens from nasal swab specimens. It is intended to aid in the rapid differential diagnosis of influenza A and/or B viral infections. A negative test is presumptive and should be confirmed by cell culture.

Cross-reactivity with other respiratory viruses in this assay has not been evaluated. The user is responsible for determining the cross-reactivity of other respiratory viruses with this test.

3. Special conditions for use statement(s): For prescription use

4. Special instrument requirements: None

# I. Device Description:

The OSOM Influenza A&B Test consists of a test stick that separately detects influenza A and B. The test procedure requires the solubilization of the nucleoproteins from a swab by mixing the swab in Extraction Buffer. The test stick is then placed in the sample mixture, which then migrates along the membrane surface. If influenza A and/or B viral antigens are present in the sample, it will form a complex with mouse monoclonal IgG antibodies to influenza A and/or B nucleoproteins conjugated to colloidal gold. The complex will then be bound by another mouse anti-influenza A and/or B antibody coated on the nitrocellulose membrane. A pink to purple control line must appear in the control region of the stick for results to be valid. The appearance of a second and possibly a third light pink to purple line will appear in the test line region indicating an A, B or A and B positive result.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Viral cell culture, Quidel QuickVue® Influenza $\mathbf { A } { + } \mathbf { B }$ Test

2. Predicate 510(k) number(s): Comparison with predicate:

Table 1: Summary of Device Similarities and Differences

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>OSOM Influenza A&amp;B Test</td><td rowspan=1 colspan=1>Quidel QuickVue® InfluenzaA+B Test</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Intended for the qualitativedetection of influenza A andinfluenza B viral antigensfrom nasal swab specimens.It is intended to aid in therapid differential diagnosis ofinfluenza A and/or B viralinfections. The test is for usein clinical laboratories, healthclinics, and physician officelaboratories.</td><td rowspan=1 colspan=1>Intended for the rapid,qualitative detection ofinfluenza type A andinfluenza type B antigensfrom nasal swab, nasal washand/or nasal aspiratespecimens. This test isintended for use as an aid inthe rapid differentialdiagnosis of acute influenzatype A and type B virusinfection.</td></tr><tr><td rowspan=1 colspan=1>Assay Format</td><td rowspan=1 colspan=1>Lateral flow immunoassay</td><td rowspan=1 colspan=1>Lateral flow immunoassay</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>- nasal swabs</td><td rowspan=1 colspan=1>- nasal swabs- nasal wash- nasal aspirate</td></tr><tr><td rowspan=1 colspan=1>Antibodies (labeledand capture)</td><td rowspan=1 colspan=1>Mouse monoclonals</td><td rowspan=1 colspan=1>Mouse monoclonals</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Colloidal gold</td><td rowspan=1 colspan=1>Latex</td></tr><tr><td rowspan=1 colspan=1>Objective Test Line</td><td rowspan=1 colspan=1>Pink to purple line</td><td rowspan=1 colspan=1>Red line</td></tr><tr><td rowspan=1 colspan=1>Internal Control</td><td rowspan=1 colspan=1>Yes - red line</td><td rowspan=1 colspan=1>Yes - blue line</td></tr><tr><td rowspan=1 colspan=1>Time To Result</td><td rowspan=1 colspan=1>10 minutes</td><td rowspan=1 colspan=1>10 minutes</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Not applicable

L. Test Principle: Immunochromatographic assay

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

# Assay Reproducibility

A reproducibility proficiency study was conducted to demonstrate that the OSOM Influenza A&B Test will perform acceptably in the hands of nurses, nurse practitioners and physicians’ office personnel. A panel of swabs including negative (no virus), strong negative (below the limit of detection), low (near the limit of detection) and mid viral levels for influenza A and B were coded and masked to the operators. This study was conducted with three operators at three health centers in the eastern United States (2 physician’s offices and 1 clinic site) and at Genzyme Diagnostics. The overall accuracy was $9 7 \%$ for flu A and $94 \%$ for flu B. Two invalid tests were considered as incorrect results in each analysis.

<table><tr><td></td><td>Correct Response for Flu A</td><td>Lower 95% Confidence Interval</td><td>Upper 95% Confidence Interval</td></tr><tr><td>A - Strong Neg</td><td>12/12 100.0%</td><td>73.0%</td><td>100.0%</td></tr><tr><td>A-Low</td><td>23/24* 95.8%</td><td>78.9%</td><td>99.9%</td></tr><tr><td>A - Med</td><td>11/12* 91.7%</td><td>61.5%</td><td>99.8%</td></tr><tr><td>B - Strong Neg</td><td>12/12 100.0%</td><td>73.0%</td><td>100.0%</td></tr><tr><td>B -Low</td><td>23/24 95.8%</td><td>78.9%</td><td>99.9%</td></tr><tr><td>B - Med</td><td>11/12 91.7%</td><td>61.5%</td><td>99.8%</td></tr><tr><td>AB - Med 12/12</td><td>100.0%</td><td>73.0%</td><td>100.0%</td></tr><tr><td>Negative 48/48</td><td>100.0%</td><td>92.5%</td><td>100.0%</td></tr><tr><td>Total</td><td>152/156* 97.4% Correct</td><td>93.6% Lower 95%</td><td>99.3%</td></tr><tr><td></td><td>Response for Flu B</td><td>Confidence Interval</td><td>Upper 95% Confidence Interval</td></tr><tr><td>A - Strong Neg</td><td>12/12 23/24*</td><td>100.0%</td><td>73.0% 100.0%</td></tr><tr><td>A-Low</td><td>95.8%</td><td>78.9%</td><td>99.9%</td></tr><tr><td>A - Med</td><td>11/12* 91.7%</td><td>61.5%</td><td>99.8%</td></tr><tr><td>B - Strong Neg</td><td>11/12 91.7%</td><td>61.5%</td><td>99.8%</td></tr><tr><td>B -Low</td><td>21/24 87.5%</td><td>67.6%</td><td>97.3%</td></tr><tr><td>B - Med</td><td>11/12 91.7%</td><td>61.5%</td><td>99.8%</td></tr><tr><td>AB - Med</td><td>12/12 100.0%</td><td>73.0%</td><td>100.0%</td></tr><tr><td>Negative 46/48</td><td>95.8%</td><td>85.7%</td><td>99.5%</td></tr><tr><td>Total</td><td>147/156* 94.2%</td><td>89.3%</td><td>97.3%</td></tr></table>

\*invalids due to insufficient volume or no control line.

b. Linearity/assay reportable range: Not applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not applicable

Dilutions of influenza A Kitakyushyu/159/93 (H3N2) and for influenza B Lee/40 virus were run in triplicate on three lots of the OSOM Influenza A&B Test. The approximate detection limits of the OSOM Influenza A&B Test are $4 . 4 \mathrm { ~ x ~ } 1 0 ^ { 4 } \mathrm { ~ T \dot { C } I D } _ { 5 0 } /$ test for influenza A and $1 . 4 4 \mathrm { ~ x ~ } 1 0 ^ { 5 } \mathrm { T C I D } _ { 5 0 } /$ /test for influenza B.

Not applicable

# e. Analytical specificity:

The OSOM Influenza A&B Test was evaluated with 25 bacterial isolates. Bacterial isolates were tested at a concentration of approximately $1 0 ^ { 8 } \mathrm { c f u / m L }$ . Very high levels of Staphylococcus aureus $( { > } 9 \mathrm { x } 1 0 ^ { 8 }  { \mathrm { \ c f u / m L } }$ ) produced a positive result. All other bacteria listed gave negative responses. Cross-reactivity with other known respiratory viruses was not evaluated. Only influenza isolates were tested.

Bacterial Panel:   
Acinetobacter calcoaceticus   
Bordetella pertussis   
Candida albicans   
Corynebacterium diphteriae   
Enterococcus faecalis   
Enterococcus gallinarum   
Escherichia coli   
Haemophilus influenza   
Klebsiella pneumoniae   
Legionella pneumophilia   
Moraxella catarrhalis   
Mycobacterium avium   
Mycobacterium tuberculosis   
Neisseria meningitidis   
Proteus mirabilis   
Proteus vulgaris   
Pseudomonas aeruginosa   
Serratia marcescens   
Staphylococcus aureus   
Staphylococcus epidermidis   
Streptococcus Group A   
Streptococcus Group B   
Streptococcus mutans   
Streptococcus pneumoniae   
Torulopsis glabrata

# Influenza A/B Panel testing

A total of 46 human and animal influenza strains were tested with the OSOM Influenza A&B test. Viral titers $\mathrm { ( T C I D _ { 5 0 } ) }$ for A/Kitakyushu/159/93 (H3N2) and $\mathrm { B } / \mathrm { L e e } / 4 0$ were determined by inoculating MDCK cells, followed by standard procedures for cell culture viral assays. Aliquots of these controls with known $\mathrm { T C I D } _ { 5 0 }$ were then used to establish a standard curve in an ELISA assay. The concentrations of other influenza viruses were determined indirectly using the ELISA assay after the viruses had been inactivated. Influenza viruses were tested at an ELISA estimated $\mathrm { T C I D } _ { 5 0 }$ as listed in the table below. All influenza virus isolates gave positive results with the test line at the expected location for the A, B and animal (positive for influenza A) isolates.

<table><tr><td rowspan=1 colspan=1>Influenza A strains:</td><td rowspan=1 colspan=1>Sub-type</td><td rowspan=1 colspan=1>EstimatedELISATCID50/mL</td></tr><tr><td rowspan=1 colspan=1>Beijing/262/95</td><td rowspan=1 colspan=1>H1N1</td><td rowspan=1 colspan=1>8.25E+07</td></tr><tr><td rowspan=1 colspan=1>Brazil/11/78</td><td rowspan=1 colspan=1>H1N1</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Chile/1/83</td><td rowspan=1 colspan=1>H1N1</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>New Jersey/8/76</td><td rowspan=1 colspan=1>H1N1</td><td rowspan=1 colspan=1>2.78E+08</td></tr><tr><td rowspan=1 colspan=1>Taiwan/1/86</td><td rowspan=1 colspan=1>H1N1</td><td rowspan=1 colspan=1>3.47E+07</td></tr><tr><td rowspan=1 colspan=1>Guizhou/54/89</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>7.54E+07</td></tr><tr><td rowspan=1 colspan=1>OMS/5389/88</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Beijing/32/92</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>3.97E+06</td></tr><tr><td rowspan=1 colspan=1>England/427/88</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>4.73E+07</td></tr><tr><td rowspan=1 colspan=1>Johannesburg/33/94</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>1.61E+07</td></tr><tr><td rowspan=1 colspan=1>Leningrad/360/86</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>2.50E+06</td></tr><tr><td rowspan=1 colspan=1>Mississippi/1/85</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Philippines/2/82</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>9.75E+07</td></tr><tr><td rowspan=1 colspan=1>Shangdong/9/93</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>1.67E+08</td></tr><tr><td rowspan=1 colspan=1>Shanghai/16/89</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>3.49E+08</td></tr><tr><td rowspan=1 colspan=1>Shanghai/24/90</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Sichuan/2/87</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Kitakyushyu/159/93</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>3.19E+08</td></tr><tr><td rowspan=1 colspan=1>Akita/1/94</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>2.90E+08</td></tr><tr><td rowspan=1 colspan=1>Beijing/262/95</td><td rowspan=1 colspan=1>H1N1</td><td rowspan=1 colspan=1>1.71E+08</td></tr><tr><td rowspan=1 colspan=1>Yamagata/32/89</td><td rowspan=1 colspan=1>H1N1</td><td rowspan=1 colspan=1>7.28E+07</td></tr><tr><td rowspan=1 colspan=1>New Caledonia/20/99</td><td rowspan=1 colspan=1>H1N1</td><td rowspan=1 colspan=1>6.86E+07</td></tr><tr><td rowspan=1 colspan=1>Panama/2007/99</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>1.40E+08</td></tr><tr><td rowspan=1 colspan=1>Wyoming/03/03</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>7.40E+06</td></tr><tr><td rowspan=1 colspan=1>Fujian/411/02</td><td rowspan=1 colspan=1>H3N2</td><td rowspan=1 colspan=1>6.12E+07</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Influenza B strains:</td><td rowspan=1 colspan=1>Sub-type</td><td rowspan=1 colspan=1>EstimatedELISATCID50/mL</td></tr><tr><td rowspan=1 colspan=1>Ann Arbor/1/86</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Beijing1/87</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.04E+07</td></tr><tr><td rowspan=1 colspan=1>Guangdong/120/2000</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>6.44E+07</td></tr><tr><td rowspan=1 colspan=1>Hongkong/8/73</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.74E+07</td></tr><tr><td rowspan=1 colspan=1>Panama/45/90</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3.79E+07</td></tr><tr><td rowspan=1 colspan=1>Singapore/222/79</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.84E+07</td></tr><tr><td rowspan=1 colspan=1>Yamagata/16/88</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.78E+07</td></tr><tr><td rowspan=1 colspan=1>Lee/40</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2.13E+08</td></tr><tr><td rowspan=1 colspan=1>Mie/1/93</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.84E+07</td></tr><tr><td rowspan=1 colspan=1>Guangdong/05/94</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.27E+07</td></tr><tr><td rowspan=1 colspan=1>Johannesburg/5/99</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>5.87E+07</td></tr><tr><td rowspan=1 colspan=1>Shandong/7/97</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.41E+07</td></tr><tr><td rowspan=1 colspan=1>Shanghai/361/2002</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>NA</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Animalinfluenza strains:</td><td rowspan=1 colspan=1>Sub-type</td><td rowspan=1 colspan=1>EstimatedELISATCID50/mL</td></tr><tr><td rowspan=1 colspan=1>A/Duck/Singapore-Q/F119-3/97</td><td rowspan=1 colspan=1>H5N3</td><td rowspan=1 colspan=1>1.65E+08</td></tr><tr><td rowspan=1 colspan=1>A/Equine/Prague/56</td><td rowspan=1 colspan=1>H7N7</td><td rowspan=1 colspan=1>5.37E+06</td></tr><tr><td rowspan=1 colspan=1>A/Duck/Wisconsin/1120/82</td><td rowspan=1 colspan=1>H5N3</td><td rowspan=1 colspan=1>2.30E+08</td></tr><tr><td rowspan=1 colspan=1>A/Hong Kong/483/97</td><td rowspan=1 colspan=1>H5N1</td><td rowspan=1 colspan=1>1.06E+08</td></tr><tr><td rowspan=1 colspan=1>A/Hong Kong/213/2003</td><td rowspan=1 colspan=1>H5N1</td><td rowspan=1 colspan=1>1.84E+08</td></tr><tr><td rowspan=1 colspan=1>A/Turkey/Ontario/71</td><td rowspan=1 colspan=1>H7N3</td><td rowspan=1 colspan=1>8.12E+07</td></tr><tr><td rowspan=1 colspan=1>A/Mallard/Wisconsin/479/79</td><td rowspan=1 colspan=1>H7N3</td><td rowspan=1 colspan=1>2.08E+08</td></tr><tr><td rowspan=1 colspan=1>A/Mallard/Saskatchewa</td><td rowspan=1 colspan=1>H7N3</td><td rowspan=1 colspan=1>2.46E+08</td></tr></table>

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with gold standard: See clinical studies.

b. Matrix comparison :

Not applicable

3. Clinical studies : A clinical trial was conducted during the 2004-2005 flu season in the United States at sites located in the east, central and west regions to establish the clinical sensitivity and clinical specificity of the OSOM Influenza A&B Test in detecting influenza A and influenza B antigens in nasal swab specimens. Sites included family practice and pediatric offices, emergency departments and clinics. All clinical samples were collected from patients with flu-like symptoms including fever, dry cough and myalgia. Nasal swab specimens were collected from a total of 383 subjects enrolled in the study. Of the 383 samples, 132 samples were from pediatric subjects (2-19 years) and 251 samples were from adults $( \geq 2 0$ years). The OSOM Influenza A&B Test was compared to cell culture to determine the comparative clinical sensitivity and clinical specificity for detection of influenza A and influenza B in nasal swab specimens

a. Clinical Sensitivity and specificity:

# Comparison of OSOM Influenza A&B Test to Cell culture: Nasal Swab

<table><tr><td colspan="5">Flu A</td></tr><tr><td>OSOM</td><td colspan="4">Culture</td></tr><tr><td>Influenza A&amp;B</td><td>A+</td><td>Negative</td><td></td><td>Total</td></tr><tr><td>A+</td><td>79</td><td>91</td><td></td><td>88</td></tr><tr><td>A+B+</td><td>0</td><td>$1^{}$</td><td></td><td>1</td></tr><tr><td>Negative</td><td>283</td><td>266</td><td></td><td>294</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total</td><td>107</td><td>276</td><td></td><td>383</td></tr></table>

Clinical sensitivity: $7 3 . 8 \%$ (79/107) ( $9 5 \%$ CI 64.4% - 81.9%)

Clinical specificity: $9 6 . 4 \%$ . (266/276) ( $9 5 \%$ CI 93.4% - 98.2%)

<table><tr><td rowspan=1 colspan=5>Flu BOSOM              CultureInfluenzaA&amp;B          B+       Negative              Total</td></tr><tr><td rowspan=1 colspan=1>B+</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1>A+B+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15}$</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>206</td><td rowspan=1 colspan=1>321</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>341</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>333</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>388</td></tr></table>

Clinical sensitivity: $6 0 . 0 \%$ (30/50) ( $9 5 \%$ CI 45.2-73.6%)

Clinical specificity: $9 6 . 4 \%$ (321/333) ( $9 5 \%$ CI 93.8% - 98.1%)

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.